{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:57:36Z","timestamp":1787669856776,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition. The cytogenetic pattern of AL shows profound similarity with that of other plasma cell disorders but harbors distinct features. AL can be classified into two primary subtypes: non-hyperdiploidy and hyperdiploidy. Non-hyperdiploidy usually involves immunoglobulin heavy chain translocations, and t(11;14) is the hallmark of this disease. T(11;14) is associated with low plasma cell count but high FLC level and displays distinct response outcomes to different treatment modalities. Hyperdiploidy is associated with plasmacytosis and subclone formation, and it generally confers a neutral or inferior prognostic outcome. Other chromosome abnormalities and driver gene mutations are considered as secondary cytogenetic aberrations that occur during disease evolution. These genetic aberrations contribute to the proliferation of plasma cells, which secrete excess FLC for amyloid deposition. Other genetic factors, such as specific usage of immunoglobulin light chain germline genes and light chain somatic mutations, also play an essential role in amyloid fibril deposition in AL. This paper will propose a framework of AL classification based on genetic aberrations and discuss the amyloid formation of AL from a genetic aspect.<\/jats:p>","DOI":"10.1186\/s40164-021-00236-z","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T08:03:03Z","timestamp":1626768183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications"],"prefix":"10.1186","volume":"10","author":[{"given":"Linchun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"issue":"1","key":"236_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.","journal-title":"Nat Rev Dis Primers"},{"key":"236_CR2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/1471-2458-12-974","volume":"12","author":"K Hemminki","year":"2012","unstructured":"Hemminki K, Li X, F\u00f6rsti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974.","journal-title":"BMC Public Health"},{"issue":"4","key":"236_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525\u201332.","journal-title":"Br J Haematol"},{"issue":"6","key":"236_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/cer-2017-0100","volume":"7","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data. J Comp Eff Res. 2018;7(6):549\u201359.","journal-title":"J Comp Eff Res"},{"issue":"26","key":"236_CR5","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","volume":"121","author":"G Merlini","year":"2013","unstructured":"Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124\u201330.","journal-title":"Blood"},{"issue":"9","key":"236_CR6","doi-asserted-by":"publisher","first-page":"e0185078","DOI":"10.1371\/journal.pone.0185078","volume":"12","author":"T Li","year":"2017","unstructured":"Li T, Huang X, Cheng S, Zhao L, Ren G, Chen W, et al. Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. PLoS ONE. 2017;12(9):e0185078.","journal-title":"PLoS ONE"},{"issue":"1","key":"236_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12876-017-0628-3","volume":"17","author":"L Tian","year":"2017","unstructured":"Tian L, Tang A, Zhang X, Mei Z, Liu F, Li J, et al. Incomplete ileus and hemafecia as the presenting features of multi-organ involved primary systemic AL amyloidosis: a rare case report. BMC Gastroenterol. 2017;17(1):72.","journal-title":"BMC Gastroenterol"},{"issue":"18","key":"236_CR8","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","volume":"116","author":"G Palladini","year":"2010","unstructured":"Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426\u201330.","journal-title":"Blood"},{"issue":"8","key":"236_CR9","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520\u201330.","journal-title":"Blood"},{"issue":"15","key":"236_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139.","journal-title":"Blood"},{"issue":"5","key":"236_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16096","volume":"187","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019;187(5):588\u201394.","journal-title":"Br J Haematol"},{"issue":"12","key":"236_CR12","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210\u201321.","journal-title":"Leukemia"},{"issue":"3","key":"236_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","volume":"97","author":"M Chesi","year":"2013","unstructured":"Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013;97(3):313\u201323.","journal-title":"Int J Hematol"},{"issue":"1","key":"236_CR14","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10(1):3835.","journal-title":"Nat Commun"},{"issue":"5","key":"236_CR15","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1038\/bcj.2015.34","volume":"5","author":"R Warsame","year":"2015","unstructured":"Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015;5(5):e310.","journal-title":"Blood Cancer J"},{"issue":"2","key":"236_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.hemonc.2017.07.005","volume":"11","author":"L Hammons","year":"2018","unstructured":"Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D\u2019Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018;11(2):105\u201311.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"236_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cam4.3683","volume":"10","author":"M Ozga","year":"2020","unstructured":"Ozga M, Zhao Q, Benson D Jr, Elder P, Williams N, Bumma N, et al. AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. Cancer Med. 2020;10:965\u201373.","journal-title":"Cancer Med"},{"issue":"7","key":"236_CR18","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","volume":"31","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562\u20139.","journal-title":"Leukemia"},{"key":"236_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.leukres.2016.03.001","volume":"44","author":"SY Kim","year":"2016","unstructured":"Kim SY, Im K, Park SN, Kim JA, Yoon SS, Lee DS. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance. Leuk Res. 2016;44:45\u201352.","journal-title":"Leuk Res"},{"issue":"26","key":"236_CR20","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","volume":"23","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"236_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/jcp.2009.065474","volume":"62","author":"M Deshmukh","year":"2009","unstructured":"Deshmukh M, Elderfield K, Rahemtulla A, Naresh KN. Immunophenotype of neoplastic plasma cells in AL amyloidosis. J Clin Pathol. 2009;62(8):724\u201330.","journal-title":"J Clin Pathol"},{"issue":"11","key":"236_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/jclinpath-2012-200819","volume":"65","author":"JC Lee","year":"2012","unstructured":"Lee JC, Wu H, Prokaeva TB, O\u2019Hara C, Seldin DC. Expression of D-type cyclins in AL amyloidosis plasma cells. J Clin Pathol. 2012;65(11):1052\u20135.","journal-title":"J Clin Pathol"},{"issue":"8","key":"236_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/leu.2016.387","volume":"31","author":"MI da Silva Filho","year":"2017","unstructured":"da Silva Filho MI, F\u00f6rsti A, Weinhold N, Meziane I, Campo C, Huhn S, et al. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia. 2017;31(8):1735\u201342.","journal-title":"Leukemia"},{"issue":"26","key":"236_CR24","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"236_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2141.2002.03438.x","volume":"117","author":"CJ Harrison","year":"2002","unstructured":"Harrison CJ, Mazzullo H, Ross FM, Cheung KL, Gerrard G, Harewood L, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 2002;117(2):427\u201335.","journal-title":"Br J Haematol"},{"issue":"20","key":"236_CR26","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","volume":"2","author":"T Bochtler","year":"2018","unstructured":"Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Kr\u00e4mer A, et al. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2018;2(20):2607\u201318.","journal-title":"Blood Adv"},{"issue":"3","key":"236_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3324\/haematol.13369","volume":"94","author":"AH Bryce","year":"2009","unstructured":"Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009;94(3):380\u20136.","journal-title":"Haematologica"},{"issue":"24","key":"236_CR28","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","volume":"116","author":"S Kumar","year":"2010","unstructured":"Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126\u20139.","journal-title":"Blood"},{"issue":"8","key":"236_CR29","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/leu.2010.128","volume":"24","author":"S Kumar","year":"2010","unstructured":"Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010;24(8):1498\u2013505.","journal-title":"Leukemia"},{"issue":"18","key":"236_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.2019003633","volume":"135","author":"CR Kimmich","year":"2020","unstructured":"Kimmich CR, Terzer T, Benner A, Dittrich T, Veelken K, Carpinteiro A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):1517\u201330.","journal-title":"Blood"},{"issue":"9","key":"236_CR31","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","volume":"111","author":"T Bochtler","year":"2008","unstructured":"Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111(9):4700\u20135.","journal-title":"Blood"},{"issue":"1","key":"236_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clml.2011.09.217","volume":"12","author":"P Zhou","year":"2012","unstructured":"Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2012;12(1):49\u201358.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"236_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","volume":"33","author":"T Bochtler","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"236_CR34","first-page":"244","volume":"27","author":"B Dumas","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid Int J Exp Clin Investig. 2020;27(4):244\u20139.","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"1","key":"236_CR35","first-page":"9","volume":"21","author":"T Bochtler","year":"2014","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone. Amyloid Int J Exp Clin Investig. 2014;21(1):9\u201317.","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"4","key":"236_CR36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","volume":"128","author":"T Bochtler","year":"2016","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128(4):594\u2013602.","journal-title":"Blood"},{"issue":"22","key":"236_CR37","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139.","journal-title":"Blood"},{"issue":"3","key":"236_CR38","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","volume":"102","author":"C Touzeau","year":"2017","unstructured":"Touzeau C, Le Gouill S, Mah\u00e9 B, Boudreault JS, Gastinne T, Blin N, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017;102(3):e112\u20134.","journal-title":"Haematologica"},{"key":"236_CR39","doi-asserted-by":"publisher","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","volume":"41","author":"A Paner","year":"2020","unstructured":"Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020;41:100643.","journal-title":"Blood Rev"},{"issue":"3","key":"236_CR40","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","volume":"103","author":"N Leung","year":"2018","unstructured":"Leung N, Thome SD, Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 2018;103(3):e135\u20137.","journal-title":"Haematologica"},{"issue":"3","key":"236_CR41","first-page":"173","volume":"26","author":"G Ghilardi","year":"2019","unstructured":"Ghilardi G, Stussi G, Mazzucchelli L, R\u00f6cken C, Rossi D, Gerber B. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Amyloid Int J Exp Clin Investig. 2019;26(3):173\u20134.","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"10","key":"236_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clml.2019.07.003","volume":"19","author":"V Premkumar","year":"2019","unstructured":"Premkumar V, Comenzo R, Lentzsch S. Venetoclax in immunoglobulin light chain amyloidosis: is this the beginning or the end? Clin Lymphoma Myeloma Leuk. 2019;19(10):686\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"236_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","volume":"10","author":"MH Sidiqi","year":"2020","unstructured":"Sidiqi MH, Al Saleh AS, Leung N, Jevremovic D, Aljama MA, Gonsalves WI, et al. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J. 2020;10(5):55.","journal-title":"Blood Cancer J"},{"issue":"1","key":"236_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","volume":"11","author":"VJ Premkumar","year":"2021","unstructured":"Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J. 2021;11(1):10.","journal-title":"Blood Cancer J"},{"key":"236_CR45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","volume":"9","author":"A Seckinger","year":"2018","unstructured":"Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, et al. CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance. Front Immunol. 2018;9:1676.","journal-title":"Front Immunol"},{"issue":"5","key":"236_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cyto.b.21636","volume":"94","author":"K Kriegsmann","year":"2018","unstructured":"Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, et al. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. Cytom B Clin Cytom. 2018;94(5):611\u201320.","journal-title":"Cytom B Clin Cytom"},{"issue":"3","key":"236_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/ng0797-260","volume":"16","author":"M Chesi","year":"1997","unstructured":"Chesi M, Nardini E, Brents LA, Schr\u00f6ck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16(3):260\u20134.","journal-title":"Nat Genet"},{"issue":"9","key":"236_CR48","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","volume":"92","author":"M Chesi","year":"1998","unstructured":"Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts. Blood. 1998;92(9):3025\u201334.","journal-title":"Blood"},{"issue":"1","key":"236_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","volume":"117","author":"E Martinez-Garcia","year":"2011","unstructured":"Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117(1):211\u201320.","journal-title":"Blood"},{"issue":"15","key":"236_CR50","first-page":"4058","volume":"60","author":"U Malgeri","year":"2000","unstructured":"Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res. 2000;60(15):4058\u201361.","journal-title":"Cancer Res"},{"issue":"5","key":"236_CR51","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0002-9440(10)64115-6","volume":"158","author":"V Perfetti","year":"2001","unstructured":"Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S, et al. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol. 2001;158(5):1599\u2013603.","journal-title":"Am J Pathol"},{"issue":"5","key":"236_CR52","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2008-03-143040","volume":"112","author":"BK Arendt","year":"2008","unstructured":"Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood. 2008;112(5):1931\u201341.","journal-title":"Blood"},{"issue":"11","key":"236_CR53","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"CJ Neuse","year":"2020","unstructured":"Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, et al. Genome instability in multiple myeloma. Leukemia. 2020;34(11):2887\u201397.","journal-title":"Leukemia"},{"issue":"4","key":"236_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u201376.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"236_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","volume":"9","author":"DR Carrasco","year":"2006","unstructured":"Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313\u201325.","journal-title":"Cancer Cell"},{"issue":"6","key":"236_CR56","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","volume":"106","author":"WJ Chng","year":"2005","unstructured":"Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106(6):2156\u201361.","journal-title":"Blood"},{"issue":"2","key":"236_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.leu.2403586","volume":"19","author":"S Wuilleme","year":"2005","unstructured":"Wuilleme S, Robillard N, Lod\u00e9 L, Magrangeas F, Beris H, Harousseau JL, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275\u20138.","journal-title":"Leukemia"},{"issue":"14","key":"236_CR58","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","volume":"117","author":"T Bochtler","year":"2011","unstructured":"Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood. 2011;117(14):3809\u201315.","journal-title":"Blood"},{"issue":"7","key":"236_CR59","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3324\/haematol.2016.160721","volume":"102","author":"M Granzow","year":"2017","unstructured":"Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, et al. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. Haematologica. 2017;102(7):1281\u201390.","journal-title":"Haematologica"},{"issue":"11","key":"236_CR60","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00432-018-2732-3","volume":"144","author":"J Mei","year":"2018","unstructured":"Mei J, Zhai Y, Li H, Li F, Zhou X, Song P, et al. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China. J Cancer Res Clin Oncol. 2018;144(11):2263\u201373.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"236_CR61","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100\u20135.","journal-title":"Blood"},{"issue":"25","key":"236_CR62","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","volume":"126","author":"ML Chretien","year":"2015","unstructured":"Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126(25):2713\u20139.","journal-title":"Blood"},{"issue":"5","key":"236_CR63","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","volume":"120","author":"JB Egan","year":"2012","unstructured":"Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060\u20136.","journal-title":"Blood"},{"issue":"5","key":"236_CR64","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067\u201376.","journal-title":"Blood"},{"issue":"1","key":"236_CR65","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41375-020-0800-6","volume":"35","author":"I Cuenca","year":"2021","unstructured":"Cuenca I, Alameda D, Sanchez-Vega B, Gomez-Sanchez D, Alignani D, Lasa M, et al. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia. 2021;35(1):245\u20139.","journal-title":"Leukemia"},{"issue":"7","key":"236_CR66","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1002\/ajh.26191","volume":"96","author":"CR Kimmich","year":"2021","unstructured":"Kimmich CR, Terzer T, Benner A, Hansen T, Carpinteiro A, Dittrich T, et al. DaraRD in systemic AL amyloidosis: high efficacy, relevant toxicity and main adverse effect of gain 1q21. Am J Hematol. 2021;96(7):E253\u20137.","journal-title":"Am J Hematol"},{"issue":"11","key":"236_CR67","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","volume":"20","author":"R Fonseca","year":"2006","unstructured":"Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034\u201340.","journal-title":"Leukemia"},{"issue":"6","key":"236_CR68","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.humpath.2011.07.013","volume":"43","author":"MH Chen","year":"2012","unstructured":"Chen MH, Qi C, Reece D, Chang H. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with bortezomib. Hum Pathol. 2012;43(6):858\u201364.","journal-title":"Hum Pathol"},{"issue":"6","key":"236_CR69","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/sj.leu.2402125","volume":"15","author":"R Fonseca","year":"2001","unstructured":"Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15(6):981\u20136.","journal-title":"Leukemia"},{"issue":"15","key":"236_CR70","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56-65.","journal-title":"Blood"},{"issue":"2","key":"236_CR71","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1038\/bcj.2017.12","volume":"7","author":"SS Chavan","year":"2017","unstructured":"Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, et al. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017;7(2):e535.","journal-title":"Blood Cancer J"},{"issue":"11","key":"236_CR72","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/j.clml.2018.07.292","volume":"18","author":"SW Wong","year":"2018","unstructured":"Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, et al. Outcome of patients with newly diagnosed systemic light-chain amyloidosis associated with deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018;18(11):e493\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"236_CR73","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2015.00288","volume":"5","author":"A Parrales","year":"2015","unstructured":"Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 2015;5:288.","journal-title":"Front Oncol"},{"issue":"2","key":"236_CR74","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cells9020287","volume":"9","author":"E Flynt","year":"2020","unstructured":"Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A. Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells. 2020;9(2):287.","journal-title":"Cells"},{"issue":"5","key":"236_CR75","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"issue":"5","key":"236_CR76","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044\u201352.","journal-title":"Leukemia"},{"issue":"10","key":"236_CR77","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","volume":"112","author":"W Xiong","year":"2008","unstructured":"Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112(10):4235\u201346.","journal-title":"Blood"},{"issue":"24","key":"236_CR78","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2015-10-673095","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035\u20139.","journal-title":"Blood"},{"issue":"26","key":"236_CR79","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2018-08-872226","volume":"132","author":"EM Boyle","year":"2018","unstructured":"Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018;132(26):2775\u20137.","journal-title":"Blood"},{"issue":"1","key":"236_CR80","first-page":"36","volume":"27","author":"XF Huang","year":"2020","unstructured":"Huang XF, Jian S, Lu JL, Shen KN, Feng J, Zhang CL, et al. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid Int J Exp Clin Investig. 2020;27(1):36\u201344.","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"3","key":"236_CR81","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1046\/j.1365-2141.1999.01591.x","volume":"106","author":"RL Comenzo","year":"1999","unstructured":"Comenzo RL, Wally J, Kica G, Murray J, Ericsson T, Skinner M, et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol. 1999;106(3):744\u201351.","journal-title":"Br J Haematol"},{"issue":"3","key":"236_CR82","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.V98.3.714","volume":"98","author":"RL Comenzo","year":"2001","unstructured":"Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714\u201320.","journal-title":"Blood"},{"issue":"3","key":"236_CR83","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","volume":"100","author":"V Perfetti","year":"2002","unstructured":"Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002;100(3):948\u201353.","journal-title":"Blood"},{"issue":"10","key":"236_CR84","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","volume":"101","author":"RS Abraham","year":"2003","unstructured":"Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801\u20138.","journal-title":"Blood"},{"issue":"11","key":"236_CR85","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1002\/art.22959","volume":"56","author":"T Prokaeva","year":"2007","unstructured":"Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum. 2007;56(11):3858\u201368.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"236_CR86","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","volume":"119","author":"V Perfetti","year":"2012","unstructured":"Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, et al. The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119(1):144\u201350.","journal-title":"Blood"},{"issue":"3","key":"236_CR87","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","volume":"129","author":"TV Kourelis","year":"2017","unstructured":"Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299\u2013306.","journal-title":"Blood"},{"issue":"8","key":"236_CR88","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/bloodadvances.2020003671","volume":"5","author":"S Sidana","year":"2021","unstructured":"Sidana S, Dasari S, Kourelis TV, Dispenzieri A, Murray DL, King RL, et al. IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. Blood Adv. 2021;5(8):2101\u20135.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"236_CR89","first-page":"92","volume":"18","author":"P Russo","year":"2011","unstructured":"Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, et al. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid Int J Exp Clin Investig. 2011;18(Suppl 1):92\u20133.","journal-title":"Amyloid Int J Exp Clin Investig"},{"issue":"7","key":"236_CR90","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/bloodadvances.2018016782","volume":"2","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv. 2018;2(7):769\u201376.","journal-title":"Blood Adv"},{"issue":"22","key":"236_CR91","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2174\/1568026611212220007","volume":"12","author":"M Ramirez-Alvarado","year":"2012","unstructured":"Ramirez-Alvarado M. Amyloid formation in light chain amyloidosis. Curr Top Med Chem. 2012;12(22):2523\u201333.","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"236_CR92","doi-asserted-by":"publisher","first-page":"e981","DOI":"10.1371\/journal.pone.0000981","volume":"2","author":"S Enqvist","year":"2007","unstructured":"Enqvist S, Sletten K, Stevens FJ, Hellman U, Westermark P. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE. 2007;2(10):e981.","journal-title":"PLoS ONE"},{"issue":"4","key":"236_CR93","doi-asserted-by":"publisher","first-page":"e5169","DOI":"10.1371\/journal.pone.0005169","volume":"4","author":"TL Poshusta","year":"2009","unstructured":"Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE. 2009;4(4):e5169.","journal-title":"PLoS ONE"},{"issue":"21","key":"236_CR94","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1016\/j.jmb.2016.08.021","volume":"428","author":"GJ Morgan","year":"2016","unstructured":"Morgan GJ, Kelly JW. The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol. 2016;428(21):4280\u201397.","journal-title":"J Mol Biol"},{"key":"236_CR95","doi-asserted-by":"publisher","first-page":"100334","DOI":"10.1016\/j.jbc.2021.100334","volume":"296","author":"GJ Rottenaicher","year":"2021","unstructured":"Rottenaicher GJ, Weber B, R\u00fchrn\u00f6\u00dfl F, Kazman P, Absmeier RM, Hitzenberger M, et al. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains. J Biol Chem. 2021;296:100334.","journal-title":"J Biol Chem"},{"issue":"1","key":"236_CR96","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1038\/s41467-021-23880-9","volume":"12","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Piccoli L, Romeo M, Barzago MM, Ravasio S, Foglierini M, et al. Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nat Commun. 2021;12(1):3532.","journal-title":"Nat Commun"},{"issue":"21","key":"236_CR97","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1111\/febs.14265","volume":"284","author":"OD Luna-Mart\u00ednez","year":"2017","unstructured":"Luna-Mart\u00ednez OD, Hern\u00e1ndez-Santoyo A, Villalba-Vel\u00e1zquez MI, S\u00e1nchez-Alcal\u00e1 R, Fern\u00e1ndez-Velasco DA, Becerril B. Stabilizing an amyloidogenic \u03bb6 light chain variable domain. FEBS J. 2017;284(21):3702\u201317.","journal-title":"FEBS J"},{"issue":"sup1","key":"236_CR98","first-page":"105","volume":"26","author":"M Maritan","year":"2019","unstructured":"Maritan M, Ambrosetti A, Oberti L, Barbiroli A, Diomede L, Romeo M, et al. Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. Amyloid Int J Exp Clin Investig. 2019;26(sup1):105\u20136.","journal-title":"Amyloid Int J Exp Clin Investig"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-021-00236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-021-00236-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-021-00236-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:24:00Z","timestamp":1699255440000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-021-00236-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1186\/s40164-021-00236-z","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}